Kelsey Cramer
Acute Care · Milwaukee, WINPI 1114418159
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Boehringer Ingelheim at 43.8% of the total. 2025 is the largest year on record at $2,813, more than ten times the $88 reported in 2021. Among acute care clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $114.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- Merck$1K
- United Therapeutics Corporation$846
- Actelion Pharmaceuticals US, Inc.$491
- Sanofi$141
- Philips North America LLC$49
- plus $185 from 5 others
What the payments were for
- Consulting fees$1,70032%
- Travel & lodging$1,09920%
- Food & beverage$2,53247%
- Education$641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 8 | $2,364 |
| Merck | 10 | $1,319 |
| United Therapeutics Corporation | 11 | $846 |
| Actelion Pharmaceuticals US, Inc. | 6 | $491 |
| Sanofi | 1 | $141 |
| Philips North America LLC | 2 | $49 |
| Electromed, Inc. | 3 | $44 |
| AstraZeneca | 2 | $41 |
| Bayer | 2 | $40 |
| GSK | 1 | $36 |
| Advanced Respiratory, Inc | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,396 in reported general payments places this provider in the 95th percentile of 127 acute care providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 85 | $2,022,042 |
| UptraviSelexipag | 68 | $1,649,836 |
| AdempasRiociguat | 63 | $886,400 |
| Orenitram ErTreprostinil Diolamine | 34 | $807,515 |
| OpsumitMacitentan | 52 | $650,111 |
| WinrevairSotatercept-Csrk | 27 | $426,582 |
| Ambrisentan | 85 | $222,736 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 156 | $131,590 |
| Dupixent PenDupilumab | 32 | $122,750 |
| JardianceEmpagliflozin | 40 | $40,752 |
| Sildenafil Citrate | 97 | $37,001 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 48 | $33,274 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $29,983 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $27,105 |
| Spiriva HandihalerTiotropium Bromide | 24 | $26,272 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $491 | $2,299,948120 claims |
| BayerAdempas | $40 | $886,40063 claims |
| MerckWinrevair, Dulera | $1,319 | $430,27839 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $36 | $192,678262 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $2,364 | $87,799110 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $41 | $39,07149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 127 acute care providers in Wisconsin.
Other acute care in Milwaukee
- Elizabeth LaufenbergMilwaukee$5K
- Julie PruettMilwaukee$2K
- Craig SchuttaMilwaukee$2K
- Lee KlemensMilwaukee$1K
- Marlo WilliamsMilwaukee$1K
- Nancy EatonMilwaukee$992
- Kailey LewisMilwaukee$550
- Gina LawallMilwaukee$522
- Renee RemingtonMilwaukee$501
- Tracy RichardsonMilwaukee$494
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.